Sung Yup Kim, MD
Vascular Surgery · New York, NYNPI 1497913149
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Medtronic at 47.4% of the total. 2025 is the largest year on record at $44,089, more than ten times the $3,144 reported in 2019. Among vascular surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 575 payments — averaging $228.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$62K
- Shockwave Medical, Inc$46K
- Endologix LLC$17K
- Silk Road Medical, Inc.$3K
- W. L. Gore & Associates, Inc.$576
- Abbott$563
- plus $2K from 10 others
Across 27 payments — averaging $1790.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$48K
What the payments were for
- Consulting fees$33,25025%
- Speaking & faculty fees$55,37542%
- Travel & lodging$7,4806%
- Food & beverage$35,45427%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 386 | $62,413 |
| Shockwave Medical, Inc | 51 | $46,306 |
| Endologix LLC | 55 | $16,770 |
| Silk Road Medical, Inc. | 42 | $2,982 |
| W. L. Gore & Associates, Inc. | 17 | $576 |
| Abbott | 4 | $563 |
| Terumo Medical Corporation | 4 | $436 |
| Penumbra, Inc. | 4 | $402 |
| Inspiremd Ltd | 1 | $369 |
| Philips North America LLC | 2 | $208 |
| Bard Peripheral Vascular, Inc. | 2 | $131 |
| Johnson & Johnson | 1 | $124 |
| Recor Medical Inc | 1 | $110 |
| Cook Medical LLC | 2 | $66 |
| Integra Lifesciences Corporation | 1 | $52 |
| Tactile Systems Technology Inc | 2 | $49 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$45,388
- HawkOne$40,743
- Alto Abdominal Stent Graft System$8,118
- Ovation iX Iliac Stent Graft$5,400
- VenaSeal$2,800
- ClosureFast$2,800
- ENROUTE Transcarotid Neuroprotection System$2,584
- IN.PACT Admiral$2,089
- ENROUTE Transcarotid Stent$1,974
- AFX2 Bifurcated Endograft System$1,600
- TurboHawk$1,128
- ENDURANT IIS$957
- Abre$878
- IN.PACT AV$804
- ENHANCE Transcarotid Peripheral Access Kit$715
- ENROUTE .014 Guidewire$543
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$438
- CHOCOLATE PTA BALLOON CATHETER$399
- Indigo System$390
- CGuard$369
How this compares
$131,558 in reported general payments places this provider in the 90th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 56 | $31,090 |
| EliquisApixaban | 20 | $12,177 |
| Ammonium Lactate | 446 | $10,235 |
| Diclofenac Sodium | 88 | $2,589 |
| Triamcinolone Acetonide | 357 | $1,959 |
| ClopidogrelClopidogrel Bisulfate | 81 | $753 |
| Naproxen | 68 | $518 |
| Cilostazol | 66 | $483 |
| Cephalexin | 779 | $440 |
| Gabapentin | 115 | $334 |
| Diazepam | 697 | $215 |
| Methylprednisolone | 21 | $126 |
| Clindamycin Hcl | 95 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $124 | $31,09056 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 405 vascular surgery providers in New York.
Other vascular surgery in New York
- Gary GelbfishNew York$1.9M
- John LantisNew York$922K
- Brian DerubertisNew York$714K
- James McKinseyNew York$616K
- Peter FariesNew York$494K
- Ajit RaoNew York$294K
- Daniel HanNew York$280K
- Todd BerlandNew York$260K
- Thomas MaldonadoNew York$249K
- Karan GargNew York$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.